Day One Biopharmaceuticals is a biotechnology business based in the US. Day One Biopharmaceuticals shares (DAWN) are listed on the NASDAQ and all prices are listed in US Dollars. Day One Biopharmaceuticals employs 125 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $12.06 |
|---|---|
| 52-week range | $5.44 - $28.35 |
| 50-day moving average | $14.13 |
| 200-day moving average | $19.42 |
| Wall St. target price | $39.56 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.17 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.06 from 2023-05-25
| 1 week (2023-05-19) | -9.73% |
|---|---|
| 1 month (2023-04-27) | -0.33% |
| 3 months (2023-02-27) | -34.24% |
| 6 months (2022-11-25) | -43.67% |
| 1 year (2022-05-27) | 110.84% |
|---|---|
| 2 years (2021-05-27) | -53.42% |
| 3 years (2020-05-27) | 4,724.00% |
| 5 years (2018-05-23) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -34.88% |
| Return on equity TTM | -56.01% |
| Profit margin | 0% |
| Book value | $4.08 |
| Market capitalisation | $982.9 million |
TTM: trailing 12 months
We're not expecting Day One Biopharmaceuticals to pay a dividend over the next 12 months.
Day One Biopharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. .
Access remote advice, planning and portfolio management from this established financial services company.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.